Literature DB >> 3878482

Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.

I J Mitchell, A J Cross, M A Sambrook, A R Crossman.   

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a profound parkinsonian state when systemically administered in monkeys and man. Previous studies have shown MPTP to be toxic to only the dopamine (DA) cells in the substantia nigra pars compacta and not to other catecholamine (CA)-containing cells. The data presented here suggest that MPTP also has a specific neurotoxic effect on the DA-containing cells of the ventral tegmental area and the noradrenaline-containing cells of the locus coeruleus in macaque monkeys with a moderate-to-severe parkinsonian syndrome. The results suggest that MPTP-induced parkinsonism in the monkey more closely replicates the neurochemical changes seen in idiopathic Parkinson's disease than previously thought.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3878482     DOI: 10.1016/0304-3940(85)90424-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  15 in total

1.  Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity.

Authors:  K K Gnanalingham; N A Milkowski; L A Smith; A J Hunter; P Jenner; C D Marsden
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Olivia Groover; Yoland Smith
Journal:  Neurobiol Dis       Date:  2016-12-30       Impact factor: 5.996

3.  Modifications of precentral cortex discharge and EMG activity in monkeys with MPTP-induced lesions of DA nigral neurons.

Authors:  D J Doudet; C Gross; M Arluison; B Bioulac
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

4.  Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  C E Clarke; S Boyce; M A Sambrook; S M Stahl; A R Crossman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

Review 5.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

Review 7.  The use of thalamotomy in the treatment of levodopa-induced dyskinesia.

Authors:  R D Page
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

Review 8.  Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

9.  Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.

Authors:  K S Rommelfanger; G L Edwards; K G Freeman; L C Liles; G W Miller; D Weinshenker
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

10.  Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey.

Authors:  J Tanaka; H Nakamura; S Honda; K Takada; S Kato
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.